4-(R,S)-(3,4-difluorophenyl)-1,6-dimethyl-3,4-dihydro-2-pyridinone-5-carboxylic acid | 265986-00-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(R,S)-(3,4-difluorophenyl)-1,6-dimethyl-3,4-dihydro-2-pyridinone-5-carboxylic acid
• 英文别名: 4-(3,4-Difluorophenyl)-1,6-dimethyl-2-oxo-3,4-dihydropyridine-5-carboxylic acid
• CAS: 265986-00-3
• 化学式: C₁₄H₁₃F₂NO₃
• 分子量: 281.259
• InChiKey: QQJAHHPZQZIRFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-N-(3-aminopropyl)-4-cyano-4-(4-fluorophenyl)piperidine 、 4-(R,S)-(3,4-difluorophenyl)-1,6-dimethyl-3,4-dihydro-2-pyridinone-5-carboxylic acid 生成 4-(R)-(3,4-difluorophenyl)-1,6-dimethyl-3,4-dihydro-2-pyridinone-5-carboxylic acid{3-[4-(4-fluorophenyl)-4-cyano-piperidine-1-yl]-propyl}amide
  参考文献：
  名称：

  Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists

  摘要：

  揭示了新型二氢吡啶酮和吡咯酮化合物及其药用盐。描述了这些化合物的合成以及它们作为α1a肾上腺素能受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生。这些化合物在其能够放松富含α1a受体亚型的平滑肌组织方面具有选择性，同时不会引起低血压。这样的组织包括尿道内膜周围的组织。因此，这些化合物的一个用途是通过允许尿液流动更畅顺来为患有良性前列腺增生的男性提供急性缓解。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合使用，从而可以实现对良性前列腺增生影响的急性和慢性缓解。

  公开号：

  US06235759B1
• 作为产物：
  描述：

  3,4-二氟苯甲醛 在 palladium on activated charcoal 丙二酸环(亚)异丙酯 、 氢气 、 sodium hydride 、 溶剂黄146 作用下， 生成 4-(R,S)-(3,4-difluorophenyl)-1,6-dimethyl-3,4-dihydro-2-pyridinone-5-carboxylic acid
  参考文献：
  名称：

  Selective α1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones

  摘要：

  A series of alpha(1a) receptor antagonists derived from a 4-aryl-3,4-dihydropyridine-2-one heterocycle is disclosed. Potency in the low nanomolar to picomolar range along with high selectivity was obtained. In vivo efficacy in a prostate contraction model in rats was observed with a few derivatives. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00696-4

文献信息

• US6235759B1
  申请人：——

  公开号：US6235759B1

  公开（公告）日：2001-05-22
• [EN] DIHYDROPYRIDINONES AND PYRROLINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS<br/>[FR] DIHYDROPYRIDINONES ET PYRROLINONES UTILISEES COMME ANTAGONISTES DE L'ADRENOCEPTEUR ALPHA 1A
  申请人：MERCK & CO INC

  公开号：WO2000025782A1

  公开（公告）日：2000-05-11

  Novel dihydropyridinone and pyrrolinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.
• Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06235759B1

  公开（公告）日：2001-05-22

  Novel dihydropyridinone and pyrrolinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

  揭示了新型二氢吡啶酮和吡咯酮化合物及其药用盐。描述了这些化合物的合成以及它们作为α1a肾上腺素能受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生。这些化合物在其能够放松富含α1a受体亚型的平滑肌组织方面具有选择性，同时不会引起低血压。这样的组织包括尿道内膜周围的组织。因此，这些化合物的一个用途是通过允许尿液流动更畅顺来为患有良性前列腺增生的男性提供急性缓解。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合使用，从而可以实现对良性前列腺增生影响的急性和慢性缓解。
• Selective α1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones
  作者：Philippe G Nantermet、James C Barrow、Harold G Selnick、Carl F Homnick、Roger M Freidinger、Raymond S.L Chang、Stacey S O'Malley、Duane R Reiss、Theodore P Broten、Richard W Ransom、Douglas J Pettibone、Timothy Olah、Carlos Forray

  DOI：10.1016/s0960-894x(99)00696-4

  日期：2000.8

  A series of alpha(1a) receptor antagonists derived from a 4-aryl-3,4-dihydropyridine-2-one heterocycle is disclosed. Potency in the low nanomolar to picomolar range along with high selectivity was obtained. In vivo efficacy in a prostate contraction model in rats was observed with a few derivatives. (C) 2000 Elsevier Science Ltd. All rights reserved.